|
|
|
|
|
| Tiradentes,R.V.; Pires,J.G.P.; Silva,N.F.; Ramage,A.G.; Santuzzi,C.H.; Futuro Neto,H.A.. |
| Serotonergic mechanisms have an important function in the central control of circulation. Here, the acute effects of three selective serotonin (5-HT) reuptake inhibitors (SSRIs) on autonomic and cardiorespiratory variables were measured in rats. Although SSRIs require 2-3 weeks to achieve their full antidepressant effects, it has been shown that they cause an immediate inhibition of 5-HT reuptake. Seventy male Wistar rats were anesthetized with urethane and instrumented to record blood pressure, heart rate, renal sympathetic nerve activity (RSNA), and respiratory frequency. At lower doses, the acute cardiovascular effects of fluoxetine, paroxetine and sertraline administered intravenously were insignificant and variable. At middle and higher doses, a... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Fluoxetine; Paroxetine; Renal nerve activity; Serotonin; Sertraline; Sympathetic activity. |
| Ano: 2014 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2014000700554 |
| |
|
|
| Pires,J.G.P.; Bonikovski,V.; Futuro-Neto,H.A.. |
| Depression found in Parkinson disease (PD) usually responds to selective serotonin reuptake inhibitors (SSRIs). Drugs that modify experimental neuroleptic catalepsy (NC) might affect extrapyramidal symptoms in PD. Therefore, the effects of SSRIs on NC were tested in mice, 26-36 g, separated by sex. Catalepsy was induced with haloperidol (H; 1 mg/kg, ip) and measured at 30-min intervals using a bar test. An SSRI (sertraline, ST; paroxetine, PX; fluoxetine) or vehicle (C) was injected ip 30 min before H. Dunnett's test was used for comparison of means. ST (1-5 mg/kg) or PX (1-5 mg/kg) attenuated NC, with a similar inhibition found in both sexes (5 mg/kg, 180 min: ST - males: 124 ± 10 vs 714 ± 15 s in C; females: 116 ± 10 vs 718 ± 6 s in C; PX - males: 106 ±... |
| Tipo: Info:eu-repo/semantics/other |
Palavras-chave: Selective serotonin reuptake inhibitors; Fluoxetine; Sertraline; Paroxetine; Extrapyramidal system; Catalepsy. |
| Ano: 2005 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001200015 |
| |
|
| |
|
|
| Nardi,A.E.; Valença,A.M.; Freire,R.C.; Mochcovitch,M.D.; Amrein,R.; Sardinha,A.; Levitan,M.N.; Nascimento,I.; de-Melo-Neto,V.L.; King,A.L.; de O. e Silva,A.C.; Veras,A.B.; Dias,G.P.; Soares-Filho,G.L.; da Costa,R.T.; Mezzasalma,M.A.; de Carvalho,M.R.; de Cerqueira,A.C.; Hallak,J.E.; Crippa,J.A.; Versiani,M.. |
| The objective of the present randomized, open-label, naturalistic 8-week study was to compare the efficacy and safety of treatment with clonazepam (N = 63) and paroxetine (N = 57) in patients with panic disorder with or without agoraphobia. Efficacy assessment included number of panic attacks and clinician ratings of the global severity of panic disorders with the clinical global impression (CGI) improvement (CGI-I) and CGI severity (CGI-S) scales. Most patients were females (69.8 and 68.4% in the clonazepam and paroxetine groups, respectively) and age (mean ± SD) was 35.9 ± 9.6 years for the clonazepam group and 33.7 ± 8.8 years for the paroxetine group. Treatment with clonazepam versus paroxetine resulted in fewer weekly panic attacks at week 4 (0.1 vs... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Paroxetine; Clonazepam; Panic disorder; Efficacy; Safety. |
| Ano: 2011 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000400015 |
| |
|
|
|
